Ddx3x-Related Neurodevelopmental Disorder

Watchlist
Retrieved
2021-01-18
Source
Trials
Genes
Drugs

Summary

Clinical characteristics.

DDX3X-related neurodevelopmental disorder (DDX3X-NDD) typically occurs in females and very rarely in males. All affected individuals reported to date have developmental delay / intellectual disability (ID) ranging from mild to severe; about 50% of affected girls remain nonverbal after age five years. Hypotonia, a common finding, can be associated with feeding difficulty in infancy. Behavioral issues can include autism spectrum disorder, attention-deficit/hyperactivity disorder and hyperactivity, self-injurious behavior, poor impulse control, and aggression. Other findings can include seizures, movement disorders (dyskinesia, spasticity, abnormal gait), vision and hearing impairment, congenital heart defects, respiratory difficulties, joint laxity, and scoliosis. Neuroblastoma has been observed in three individuals.

Diagnosis/testing.

The diagnosis of DDX3X-NDD is established in a female proband with suggestive findings and a heterozygous de novo DDX3X pathogenic variant identified by molecular genetic testing and in a male proband with suggestive findings and a hemizygous DDX3X pathogenic variant.

Management.

Treatment of manifestations: Treatment is symptomatic and focuses on optimizing the individual's abilities using a multidisciplinary approach that should also include psychosocial support for family members. Management of feeding difficulty, ID, behavioral issues, seizures, spasticity and other movement disorders, vision and hearing impairment, congenital heart defects, respiratory difficulties, joint laxity, and scoliosis as per standard care.

Surveillance: Periodic evaluation by the multidisciplinary team regarding growth, developmental progress and educational needs, and psychiatric/behavioral issues; regular assessment of vision and hearing, of the spine for scoliosis, for seizure control (when relevant), and for cardiac and respiratory issues. Starting at age eight years, assess girls for evidence of precocious puberty.

Genetic counseling.

DDX3X-NDD is an X-linked disorder.

  • Females. Most female probands represent simplex cases (i.e., a single occurrence in a family) and have the disorder as the result of a de novo pathogenic variant.
  • Males. DDX3X-NDD in males is caused by either a pathogenic variant inherited from an unaffected heterozygous mother or a de novo pathogenic variant. If the mother of an affected male has a DDX3X pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be heterozygotes and are not expected to manifest a neurodevelopmental phenotype.

If the proband is female and represents a simplex case and if the DDX3X pathogenic variant cannot be detected in the leukocyte DNA of either parent – or the proband is male and the DDX3X pathogenic variant cannot be detected in the leukocyte DNA of the mother – the risk to sibs is slightly greater than that of the general population (though still <1%) because of the possibility of parental germline mosaicism.

Once the DDX3X pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible.

Diagnosis

Formal diagnostic criteria for DDX3X-related neurodevelopmental disorder (DDX3X-NDD) have not been established.

Suggestive Findings

DDX3X-NDD can be considered in an individual with several of the following clinical and brain imaging findings [Snijders Blok et al 2015, Lennox et al 2020].

Clinical findings

  • Developmental delay (DD) or mild to severe intellectual disability (ID)
  • Hypotonia (primarily truncal)
  • Behavior problems: autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), inappropriate behavior, self-injurious behavior, poor impulse control and aggression
  • Language impairment, often with significant verbal dyspraxia
  • Borderline microcephaly
  • Dysmorphic facial features. Although there are no characteristic dysmorphic features, a long and/or hypotonic face, a high and/or broad forehead, and a wide nasal bridge and/or bulbous upturned nasal tip are frequently observed (Figure 1) [Snijders Blok et al 2015, Fieremans et al 2016].
Figure 1.

Figure 1.

Facial profiles of females heterozygous for a de novo DDX3X pathogenic variant Facial features of 30 of 38 females with a de novo DDX3X pathogenic variant. Common facial features include a long and/or hypotonic face, a high and/or broad forehead, a wide (more...)

Brain MRI findings in decreasing order of frequency:

  • Corpus callosum hypoplasia ranging from complete agenesis (rare) to a milder malformation with only a thin posterior body and splenium (common)
  • Ventricular enlargement and/or keyhole-shaped temporal horns of the lateral ventricles
  • Polymicrogyria
  • Other. Decreased white matter volume, decreased cingulum bundle density, diminished anterior commissure, small pons and small inferior cerebellar vermis

Establishing the Diagnosis

Female proband. The diagnosis of DDX3X-NDD is usually established in a female proband with suggestive findings and a heterozygous de novo DDX3X pathogenic variant identified by molecular genetic testing (see Table 1).

Male proband. The diagnosis of DDX3X-NDD is established in a male proband with suggestive findings and either a hemizygous DDX3X pathogenic variant inherited from an unaffected heterozygous female or a hemizygous DDX3X de novo variant identified by molecular genetic testing (see Table 1).

Note: Identification of a heterozygous DDX3X variant of uncertain significance in a female or a hemizygous DDX3X variant of uncertain significance in a male does not establish or rule out a diagnosis of DDX3X-NDD.

Molecular Genetic Testing

Because the phenotype of DDX3X-NDD is indistinguishable from many other genetic disorders with intellectual disability, recommended molecular genetic testing approaches include use of a multigene panel or comprehensive genomic testing.

Note: Single-gene testing (sequence analysis of DDX3X, followed by gene-targeted deletion/duplication analysis) is rarely useful and typically NOT recommended.

  • An intellectual disability (ID) or hypotonia (for young children) multigene panel that includes DDX3X and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. Of note, some panels for ID may not (yet) include this gene. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis and/or other non-sequencing-based tests.
    For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
  • Comprehensive genomic testing does not require the clinician to determine which gene(s) are likely involved. Exome sequencing is most commonly used; genome sequencing is also possible.
    Exome array (when clinically available) may be considered if exome sequencing is non-diagnostic. Copy number variation in DDX3X has not been studied in detail, but deletions are found in females and duplications in both genders (see Decipher Database).
    For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

Table 1.

Molecular Genetic Testing Used in DDX3X-Related Neurodevelopmental Disorder

Gene 1MethodProportion of Probands with a Pathogenic Variant 2 Detectable by Method
DDX3XSequence analysis 3,4100% 5
Gene-targeted deletion/duplication analysis 6Unknown 7
1.

See Table A. Genes and Databases for chromosome locus and protein.

2.

See Molecular Genetics for information on variants detected in this gene.

3.

Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.

4.

Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion on the X chromosome in affected males; confirmation requires additional testing by gene-targeted deletion/duplication analysis.

5.

Snijders Blok et al [2015], Wang et al [2018], Beal et al [2019], Lennox et al [2020]

6.

Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

7.

No data on gene-targeted deletions/duplications are available.

Clinical Characteristics

Clinical Description

DDX3X-related neurodevelopmental disorder (DDX3X-NDD) typically occurs in females and rarely in males. DDX3X-NDD in both females and males is associated with a broad spectrum of clinical features with variable expression and severity. Table 2 presents the most common clinical characteristics observed in the three largest cohorts of females with DDX3X-NDD observed to date comprising a total of 149 unique individuals [Snijders Blok et al 2015, Wang et al 2018, Lennox et al 2020]. Note that data from individuals included in more than one report were removed. Data from four smaller reports are included in the discussion following Table 2 [Kellaris et al 2018, Beal et al 2019, Nicola et al 2019, Scala et al 2019].

Characteristics typically present are intellectual disability (ID), tone abnormalities, and associated feeding difficulty, joint laxity, and scoliosis. Other common features include ophthalmologic abnormalities, hearing loss, congenital heart defects, and respiratory difficulties. Neuroblastoma has been observed in three individuals, all of whom presented early in life and responded favorably to treatment.

Table 2.

Clinical Findings in Females with DDX3X-Related Neurodevelopmental Disorder

FindingReport 1 [Snijders Blok et al 2015]Report 2 [Wang et al 2018]Report 3 [Lennox et al 2020]
DD/ID38/38 (100%)28/28 (100%)84/84 (100%)
Behavior issues20/38 (53%)6/28 (21%)See footnote 1.
Hypotonia29/38 (76%)19/28 (68%)66/83 (80%)
Hypertonia alone or a mixture of hyper- & hypotoniaSee footnote 2.2/12 (17%)38/83 (46%)
Epilepsy/seizures6/38 (16%)NA17/83 (20%)
Movement disorders17/38 (45%) 217/28 (61%)18/83 (22%)
Microcephaly12/38 (32%)7/28 (25%)25/74 (34%)
Vision problems13/38 (34%)9/28 (32%)32/82 (39%)
RespiratoryN/A5/28 (18%)N/A
Congenital heart abnormalitiesN/A5/7 3 (71%)11/82 (13%)
Skeletal (scoliosis)4/38 (11%)N/A8/82 (10%)
Hearing impairment3/38 (8%)N/A4/78 (5%)
Precocious puberty5/38 (13%)N/A7/82 (9%)
Cleft lip/palate/uvula3/38 (8%)N/AN/A

Note: Some overlap of participants exists in the three reported cohorts; to address the overlap, cohort 1 has been reported in its entirety and the overlaps subtracted from cohorts 2 and 3. One male overlaps in Reports 1 and 2, but (being male) is not counted in the table. Twenty of the 104 females in Report 3 were previously reported.

DD = developmental delay; ID = intellectual disability; NA = not applicable (not specified or reported in the study)

1.

In Lennox et al [2020], 49 children were assessed using the Child Behavior Checklist (CBCL) self-reported by parents. The mean CBCL was 58.3, with a SD of 10 – significantly different from neurotypical controls, p<0.001.

2.

In Snijders Blok et al [2015], movement disorders include spasticity.

3.

Evaluated by echocardiogram

DDX3X-Related Neurodevelopmental Disorder in Females

Developmental delay/disability. All females with DDX3X-NDD reported to date (within the limits of ascertainment) likely meet criteria for ID (or developmental delays when too young for the diagnosis of a disability), ranging from mild to severe [Snijders Blok et al 2015, Wang et al 2018, Lennox et al 2020].

Systematic IQ testing has not been published for females with DDX3X-NDD, so in most instances the term ID is inferentially chosen from parentally reported delayed milestones. In one report four categories were identified: 10/38 individuals with mild or moderate ID, 10/38 with moderate or moderate to severe ID, 15/38 with severe ID, and 3/38 with developmental delay (DD) who were younger than age five years [Snijders Blok et al 2015].

In another study, in which the parents of 53 affected girls used the Vineland Adaptive Behavior Scales (VABS) to self-report their child's adaptive behavioral skills, the mean composite standard score was 56.6, which is significantly below the mean score of 100 (SD 15) in the neurotypical population.

In addition, affected individuals with polymicrogyria (PMG) were more delayed developmentally, with an average VABS of 43.8 versus 57.5 in those without PMG (p<0.05) [Lennox et al 2020].

Speech/language delays or disorders are common: After age five years, 52% of females with DDX3X-NDD were nonverbal [Lennox et al 2020]. While a systematic review of progression of milestones has not been reported, in one report a female age 47 years was reported to have learned to sit at age two years, walk at age eight years, and say simple words [Wang et al 2018]. Data on the use of sign language or alternative communication methods have not been reported.

Behavioral issues include autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD) and hyperactivity, self-injurious behavior, poor impulse control, aggression, and other inappropriate behaviors [Snijders Blok et al 2015, Wang et al 2018, Lennox et al 2020]. In one study of 42 individuals, scores on the Social Communication Questionnaire completed by parents/caregivers indicated that 67% were above the at-risk threshold for ASD [Lennox et al 2020].

Tone abnormalities included either isolated hypotonia or a mixture of hypertonia and hypotonia in which truncal tone is lower and limb tone is increased.

Movement disorders are present at a young age and can include dyskinesia, ataxia, and dystonia, sometimes expressed as a stiff-legged or wide-based gait. One female was reported to have striking dystonic episodes [Beal et al 2019].

Seizure types include myoclonic-atonic seizures (episodes of brief shock-like jerks of a muscle or group of muscles as well as drop attacks), infantile spasms, focal partial seizures, or generalized absence spells. Seizures are more common in females with polymicrogyria [Lennox et al 2020].

Microcephaly is more frequent in persons with polymicrogyria (6/9) [Lennox et al 2020], nearly all of whom had an occipital frontal circumference 2 to 3 SDs below the mean.

Ophthalmologic problems include refractive errors, cortical visual impairment, optic atrophy, coloboma (type not specified in 4/92 individuals in Lennox et al), nystagmus, and strabismus (25/92, or 27%) [Wang et al 2018, Lennox et al 2020].

Respiratory problems can include obstructive sleep apnea, tachypnea, and chronic respiratory failure [Wang et al 2018].

Cardiac abnormalities, in addition to those included in Table 2, include atrial septal defect (ASD), patent ductus arteriosus (PDA), and patent foramen ovale (PFO) [Nicola et al 2019], ASD and VSD (ventricular septal defect) [Dikow et al 2017], and (in 1 of 6 females) a VSD [Beal et al 2019].

Skeletal. Scoliosis is likely secondary to hypotonia. In one report 37% (14/38) of individuals had joint laxity [Snijders Blok et al 2015].

Hearing impairment can be conductive, sensorineural, or both. Age of onset is unknown; whether hearing loss is progressive or not is unknown.

Precocious puberty (defined as onset of pubertal changes before age 8 years in girls and age 9 years in boys). While observed in a minority of females [Snijders Blok et al 2015, Lennox et al 2020], the real frequency may be higher, as both cohorts include females younger than the average age at which precocious puberty is observed.

Other

  • Gastrointestinal manifestations reported include feeding problems, gastroesophageal reflux, and constipation. There are isolated cases of anal atresia or stenosis, esophagitis, intestinal volvulus, and cyclic vomiting [Dikow et al 2017; Lennox et al 2020].
  • Cleft lip, palate or uvula is reported in a few individuals [Snijders Blok et al 2015, Fieremans et al 2016].
  • Malignancy. It is currently unclear whether the risk for specific malignancies is increased in children with germline DDX3X pathogenic variants.
    Neuroblastoma has been observed in three females ages 4-7 months [Lennox et al 2020; Sherr, personal communication]. In two of the three, neuroblastoma was detected incidentally (while obtaining spine MRIs). All three were disease free at annual follow ups [Sherr & Johnson-Kerner, personal communication].
    A pilocytic astrocytoma, incidentally found on head imaging, was reported in a female age eight years [Scala et al 2019].

DDX3X-Related Neurodevelopmental Disorder in Males

To date, males from at least ten different families have been reported with a hemizygous DDX3X variant [Snijders Blok et al 2015, Kellaris et al 2018, Wang et al 2018]. While data are insufficient to characterize a detailed phenotype, all males had intellectual disability, ranging from mild to severe.

In one report, two of five males had a head circumference less than 2 SD below the mean [Snijders Blok et al 2015]. In another report, two brothers had macrocephaly – the significance of which is unknown as it was also present in the otherwise asymptomatic father and sister [Kellaris et al 2018].

Additional features similar to those reported in affected females included behavioral problems, spasticity, tremor, hypotonia, vision problems, congenital heart disease, and delayed puberty [Snijders Blok et al 2015, Nicola et al 2019]. Brain MRI anomalies include corpus callosum abnormalities, ventriculomegaly, and white matter abnormalities.

Genotype-Phenotype Correlations

Females. Affected females with a subset of missense variants generally are more severely affected than those with truncating variants [Lennox et al 2020].

Polymicrogyria has been associated with missense or in-frame deletions [Lennox et al 2020].

Males. While all affected males have had missense DDX3X variants (see Table 6), their female relatives who are heterozygous for the same DDX3X variant do not manifest an atypical neurodevelopmental phenotype.

Prevalence

Although DDX3X-NDD is rare, variants in DDX3X are among the most commonly reported causes in females with neurodevelopmental disorders [Fitzgerald et al 2015]:

  • In one study that included more than 6,000 individuals, variants in DDX3X accounted for 1%-3% of unexplained intellectual disability in females [Snijders Blok et al 2015].
  • Another study reported that among approximately 450 genes, the occurrence of de novo variants ranked third in DDX3X, after the genes ARID1B and ANKRD11 [Wang et al 2018].

Differential Diagnosis

Because the phenotypic features associated with DDX3X-related neurodevelopmental disorder in females are not sufficient to diagnose this condition, many disorders with intellectual disability (ID) without other clearly distinctive findings should be considered in the differential diagnosis (including autism spectrum disorder and cerebral palsy). To date more than 180 such disorders with ID have been identified. See OMIM Phenotypic Series: Autosomal dominant ID, Autosomal recessive ID, Nonsyndromic X-linked ID, and Syndromic X-linked ID.

Two females with features of Toriello-Carey syndrome (T-CS) (anal atresia, congenital heart defects, corpus callosum anomalies, hypotonia, and developmental delay) (OMIM 217980) were found to have a DDX3X variant [Dikow et al 2017]. T-CS, a disorder with significant phenotypic variability [Toriello et al 2003], was first described as postnatal growth delay and microcephaly, intellectual disability, abnormal corpus callosum, Robin sequence, laryngeal abnormalities, cardiac defects, typical facial features, and other abnormalities [Toriello & Carey 1988]. T-CS is genetically heterogeneous, as various cytogenetic changes and UBE3B variants have been reported as causative [Toriello & Hatchwell 2008, McGoey et al 2010, Basel-Vanagaite et al 2014].

Management

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with DDX3X-related neurodevelopmental disorder (DDX3X-NDD), the evaluations summarized in Table 3 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

Table 3.

Recommended Evaluations Following Initial Diagnosis in Individuals with DDX3X-Related Neurodevelopmental Disorder

System/ConcernEvaluationComment
ConstitutionalAssess height, weight, & head circumference.Check for evidence of FTT.
NeurodevelopmentNeurodevelopmental assessment to identify delaysTo incl motor, speech/language eval, general cognitive, & adaptive skills by available & appropriate services (e.g., eval by early intervention program (ages 0-3 yrs), public school district (ages 3-21 yrs) , or possibly by developmental/behavioral pediatrician
Speech & languageEval by speech & language pathologistAssessment of speech, language, & communication abilities
NeurologicNeurologic eval for hypotonia, movement disorder, spasticityIf seizures are suspected: EEG & consideration of brain MRI
Psychiatric/
Behavioral
Consider assessment by behavioral pediatrician to assess maladaptive behaviors or by psychiatrist for more severe behavioral issues.Persons age >12 mos: incl screening for behavior problems, e.g., sleep disturbances, ADHD, anxiety, &/or traits suggestive of ASD.
CardiovascularEval by cardiologist
  • Especially those w/FTT & feeding difficulties
  • Consider autonomic instability in those w/syncope, tachycardia, &/or orthostatic hypotension
RespiratoryEval by pulmonologistPatients w/apnea, tachypnea, other respiratory manifestations, &/or respiratory failure
Gastrointestinal/
Feeding
Gastroenterology / nutrition / feeding team evaluationIf feeding difficulties, GERD, &/or FTT are present:
  • Swallowing, feeding, & nutritional status assessment to determine safety of oral vs gastrostomy feeding
  • Mgmt of constipation, if present
MusculoskeletalOrthopedics / physiatry / PT / OT eval
  • Eval for scoliosis if referred by pediatrician
  • Determination of DME needs
Eyes/VisionOphthalmologic examExam for refractive errors, cortical visual impairment, optic atrophy, coloboma, nystagmus, & strabismus
Hearing lossAudiologic evalFor SNHL, conductive HL, or both
Genetic counselingBy genetics professionals 1To inform affected persons & families re nature, MOI, & implications of DDX3X-NDD in order to facilitate medical & personal decision making
Family support/
resources
Assess:
  • Use of community or online resources such as Parent to Parent;
  • Need for social work involvement for parental support.

ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; DME = durable medical equipment; FTT = failure to thrive; GERD = gastroesophageal reflux disease; MOI = mode of inheritance; OT = occupational therapy; PT = physical therapy; SNHL = sensorineural hearing loss

1.

Medical geneticist, certified genetic counselor, certified advanced genetic nurse

Treatment of Manifestations

Treatment should be targeted to patient needs.

Table 4.

Treatment of Manifestations in Individuals with DDX3X-Related Neurodevelopmental Disorder

Manifestation/
Concern
TreatmentConsiderations/Other
DD/IDSee Developmental Delay / Intellectual Disability Educational Issues.
Speech &
language
By speech & language pathologistUse of Augmentative and Alternative Communication strategies as needed
MusculoskeletalOrthopedics / physical medicine & rehabilitation / PT/OT incl stretching to help avoid contractures & falls
  • For those w/scoliosis: consider bracing to prevent progression & secondary morbidity (e.g., pain, impaired ambulation, restrictive lung disease).
  • For those w/hypotonia/hypertonia: consider ankle-foot orthoses. If hypertonia is present evaluate need for spasticity treatment (e.g., baclofen, Botox®).
  • Consider need for positioning & mobility devices, disability parking placard.
SeizuresStandardized treatment w/AEDs by experienced neurologist
  • Many AEDs may be effective; none has been demonstrated effective specifically for DDX3X-NDD.
  • Education of parents/caregivers 1
Psychiatric/
Behavioral
See Developmental Delay / Intellectual Disability Educational Issues.